JP2024540015A5 - - Google Patents

Info

Publication number
JP2024540015A5
JP2024540015A5 JP2024525058A JP2024525058A JP2024540015A5 JP 2024540015 A5 JP2024540015 A5 JP 2024540015A5 JP 2024525058 A JP2024525058 A JP 2024525058A JP 2024525058 A JP2024525058 A JP 2024525058A JP 2024540015 A5 JP2024540015 A5 JP 2024540015A5
Authority
JP
Japan
Prior art keywords
braf
cancer
inhibitor
raf
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078771 external-priority patent/WO2023076991A1/en
Publication of JP2024540015A publication Critical patent/JP2024540015A/ja
Publication of JP2024540015A5 publication Critical patent/JP2024540015A5/ja
Pending legal-status Critical Current

Links

JP2024525058A 2021-10-28 2022-10-27 異常な細胞成長を処置するための併用療法 Pending JP2024540015A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272899P 2021-10-28 2021-10-28
US63/272,899 2021-10-28
PCT/US2022/078771 WO2023076991A1 (en) 2021-10-28 2022-10-27 Combination therapy for treating abnormal cell growth

Publications (2)

Publication Number Publication Date
JP2024540015A JP2024540015A (ja) 2024-10-31
JP2024540015A5 true JP2024540015A5 (cg-RX-API-DMAC7.html) 2025-11-05

Family

ID=86158717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525058A Pending JP2024540015A (ja) 2021-10-28 2022-10-27 異常な細胞成長を処置するための併用療法

Country Status (10)

Country Link
US (1) US20250009746A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422617A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540015A (cg-RX-API-DMAC7.html)
KR (1) KR20240095266A (cg-RX-API-DMAC7.html)
CN (1) CN118510505A (cg-RX-API-DMAC7.html)
AU (1) AU2022376939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235499A1 (cg-RX-API-DMAC7.html)
IL (1) IL312248A (cg-RX-API-DMAC7.html)
MX (1) MX2024005024A (cg-RX-API-DMAC7.html)
WO (1) WO2023076991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN117940130A (zh) * 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2025010293A2 (en) * 2023-07-03 2025-01-09 Immuneering Corporation Mek immune oncology inhibitor pharmaceutical compositions
CN116570599B (zh) * 2023-07-04 2023-10-20 四川大学华西医院 Vs6766联合ly3009120的应用及药物组合物
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016014481B1 (pt) * 2013-12-20 2022-11-08 Biomed Valley Discoveries, Inc Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
WO2015179075A1 (en) * 2014-05-21 2015-11-26 The Board Of Regents Of The University Of Texas System Treatment for melanoma
JP6864990B2 (ja) * 2015-04-16 2021-04-28 日東電工株式会社 Braf遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
WO2019032561A1 (en) * 2017-08-07 2019-02-14 Evol Science LLC COMBINATIONS FOR THE TREATMENT OF CANCER
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer

Similar Documents

Publication Publication Date Title
CN115624550B (zh) 一种用于治疗胃癌的喹啉衍生物
JP7611855B2 (ja) ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
JP2013507415A5 (cg-RX-API-DMAC7.html)
AU2015360095A1 (en) Quinoline derivative against non-small cell lung cancer
JP2024505680A5 (cg-RX-API-DMAC7.html)
WO2025157162A1 (zh) Fak抑制剂与kras g12c抑制剂的联用
KR102490547B1 (ko) 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물
JP2021169474A (ja) がんの処置において使用するための、Notch阻害剤およびPI3K/mTOR阻害剤を用いた併用療法
TWI866427B (zh) 雌激素受體降解劑之給藥方案
WO2016091165A1 (zh) 治疗非小细胞肺癌的喹啉衍生物
TW202402290A (zh) 癌症治療
WO2017118401A1 (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
JP2024502446A5 (cg-RX-API-DMAC7.html)
CN100408036C (zh) 阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途
WO2024088275A1 (zh) 一种萘酰胺化合物治疗耐药性肿瘤的用途
WO2004081012A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
WO2020057536A1 (zh) 用于治疗脑肿瘤的喹啉衍生物
CN117462553A (zh) 药物组合产品以及组合疗法
US20210205272A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
EP3854396A1 (en) Quinoline derivative used for treating small cell lung cancer
CN115487188A (zh) 治疗鼻咽癌的喹啉衍生物
Mathew et al. Clinical Evidence of Regorifenib in Metastatic Colorectal Cancer: A Case Report
WO2016091167A1 (zh) 抗肺鳞癌的喹啉衍生物
WO2024206147A1 (en) Dosage regimens of estrogen receptor degraders
CN108472293A (zh) 用于癌症的联合疗法